The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

US Co. To Regain All Rights to Its AGHD Diagnostic Test

Research Report
  ()
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report.

MRI Device Maker's Earnings Come In at High End of Forecasts

Research Report
  ()
IRadimed Corp. reported Q2/22 financial results that were modestly higher than expected. ROTH Capital Partners LLC advised in a research update that based on the company's higher revenues, improved margins, and disciplined cost control measures it is maintaining its Buy rating on IRadimed and raising its price target to $42/share (up from $40).

Showing Results: 1 to 2 of 2